BridgeBio Pharma Pre-Tax Income 2018-2024 | BBIO

BridgeBio Pharma pre-tax income from 2018 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
BridgeBio Pharma Annual Pre-Tax Income
(Millions of US $)
2023 $-653
2022 $-485
2021 $-586
2020 $-505
2019 $-289
2018 $-169
2017 $-44
BridgeBio Pharma Quarterly Pre-Tax Income
(Millions of US $)
2024-06-30 $-76
2024-03-31 $-36
2023-12-31 $-170
2023-09-30 $-179
2023-06-30 $-161
2023-03-31 $-143
2022-12-31 $-141
2022-09-30 $-140
2022-06-30 $-3
2022-03-31 $-201
2021-12-31 $-152
2021-09-30 $-161
2021-06-30 $-102
2021-03-31 $-171
2020-12-31 $-135
2020-09-30 $-130
2020-06-30 $-136
2020-03-31 $-104
2019-12-31 $-84
2019-09-30 $-61
2019-06-30 $-74
2019-03-31 $-69
2018-12-31
2018-09-30 $-42
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.911B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00